David Planchard

Today, we will discuss how to integrate, uh, the HER2-targeted therapies into treatment pathways in non-small cell lung cancer, how to incorporate, uh, real-world factors such as, uh, patient eligibility, comorbidities, and performance status, and importantly, how to monitor and manage, uh, toxicities such as interstitial lung disease and gastrointestinal events.

So and it's a true honor to be able to share, uh, the data and experiences, uh, regarding therapeutic approaches, uh, for HER2-positive patients with Dr. David Planchard.

Uh, David, if you could please introduce yourself.

Hello, Enriqueta.

Hello, hello, everyone.

So David Planchard.

So I'm thoracic oncologist.

I'm working at, uh, Gustave Roussy, Villejuif, France, and mainly taking care of patient, uh, with lung cancer, non-small cell, uh, but also mesothelioma.

Yes.

So the next speaker will be our chair, uh, Professor David Planchard, implementing optimal ca- optimal care in addressing AEs in HER2 overexpressing non-small cell lung cancer.

Thanks so much, Egbert Jordans.

[audience applauding] So, uh, let's move about potential toxicity and particularly the ILD.

Yes.

So the next speaker will be our chair, uh, Professor David Planchard, implementing optimal ca-- optimal care and addressing AEs in HER2 overexpressing non-small cell lung cancer.

Thanks so much, Egbert Solecht.

[clapping] So let's move about potential toxicity and particularly the ILD.

So the next speaker will be our chair.

Professor David Planchard, Implementing Optimal Mental Care and Addressing A.E.s in her two over-expression, non-spontaneous...

So let's move about potential toxicity, and particularly the ILD.

First, you can scan the QR code, question patient metastatic non-small cell lung cancer receiving TdXD 5.4 mg per kick and has an ongoing tumor response.

So the next speaker will be our chair.

Professor David Planchard, Implementing Optimal Care and Addressing A.E.s, in her two overexpression, non-sponsored, long-term.

Thank

you.

So the next speaker will be our chair.

Professor David Planchard, Implementing Optimal Mental Care and Addressing A.E.s in her two over-expression, non-spontaneous...

So let's move about potential toxicity, and particularly the ILD.

First, you can scan the QR code, question patient metastatic non-small cell lung cancer receiving TdXD 5.4 mg per kick and has an ongoing tumor response.

Yes.

So the next speaker will be our chair, uh, Professor David Planchard, implementing optimal car- optimal care and addressing AEs in HER2 overexpressing non-small cell lung cancer.

Thanks so much, Egbert Solecht.

[audience applauding] So let's move about potential toxicity and particularly the ILD.